Bladder Cancer
Bladder cancer is a condition characterized by the abnormal growth and replication of malignant epithelial cells in the tissues of the urinary bladder, leading to symptoms such as blood in the urine, pain with urination, and low back pain.
Health Outcomes
- Activated p53/BAX-Mediated DNA Damage Response
- Delayed Tumor Onset
- Enhanced Anticancer Capacity
- Enhanced Antitumor Immunity
- Enhanced CD8+ T Cell Infiltration
- Enhanced Natural Killer Cell Activity
- Enhanced Natural Killer Cell Tumor Killing Activity
- Genitourinary Adverse Events
- Improved Chemotherapy Efficacy
- Improved Effectiveness in Cancer Treatment
- Improved Natural Killer Cell Activation
- Improved Oncolytic Virotherapy Efficacy
- Improved Overall Survival
- Improved Progression-free Survival
- Improved Response to Immune Checkpoint Inhibitor Therapy
- Improved Response to PD-1 Immunotherapy
- Improved Survival Capacity
- Improved Survival Rate
- Improved Tumor Response
- Improved Urogenital Tract Symptoms
- Inactivated Other Receptor Tyrosine Kinase Activity
- Increased Binding of Carcinogenic Compounds
- Increased Cell Death
- Increased Intratumoral CD8+ T-cell Expansion
- Increased Polyamine Levels
- Increased Telomere Length
- Increased Tissue Invasion
- Inhibited Epithelial-Mesenchymal Transition
- Inhibited PI3K/AKT Pathway
- Occurrence of Unrelated Haematuria
- Protected Bladder Microbiome
- Reduced Apoptosis Due to Carcinogens
- Reduced Benzo(a)pyrene Levels
- Reduced CEA Levels
- Reduced Cancer Progression
- Reduced Cancer Risk
- Reduced Caspase-3 Activity
- Reduced Cell Adhesion
- Reduced Cumulative Incidents of CIDs in Smokers
- Reduced Epithelial-Mesenchymal Transition
- Reduced Hydronephrosis
- Reduced Recurrence Risk
- Reduced Risk of Cancer
- Reduced Tumor Downstaging
- Reduced Tumor Formation
- Reduced Tumor Grade
- Reduced Tumor Growth
- Reduced Tumor Stage
- Reduced Tumor Volume
- Reduced Urinary Urgency
- Selective Sparing of Normal Urothelial Cells
- Targeted Tumor Reduction